Medecine & Droit最新文献

Le concept de race : serpent de mer de la pratique médicale 种族概念：医疗实践汪洋中的一条蛇

IF 0.1

Medecine & Droit Pub Date : 2024-09-11 DOI: 10.1016/j.meddro.2024.07.002

Dr Alexandre Geoffroy M.D.

引用次数: 0

Parcours de soins rénové, e-santé et maillage officinal : une réponse complexe à la pénurie de médecins 改革护理路径、电子健康和药房网络：应对医生短缺的复杂对策

IF 0.1

Medecine & Droit Pub Date : 2024-09-11 DOI: 10.1016/j.meddro.2024.07.003

Marie-Catherine Concé Chemtob (Maître de conférences à l’UFR Santé, université Rouen Normandie)

引用次数: 0

La loi du 10 mai 2024 contre les dérives sectaires : application dans le domaine de la santé : séparer le bon grain scientifique de l’ivraie charlatanesque 2024 年 5 月 10 日的反宗派反常现象法：在卫生领域的应用：从江湖骗子中分离出科学小麦

IF 0.1

Medecine & Droit Pub Date : 2024-08-31 DOI: 10.1016/j.meddro.2024.08.001

Bruno Py (Professeur de droit privé et sciences criminelles)

引用次数: 0

The quest for the Benjamin Button effect in Silicon Valley: Bioethical and ecological issues posed by the longevity and immortality industry 硅谷对本杰明-巴顿效应的追求：长寿和永生产业带来的生物伦理和生态问题

IF 0.1

Medecine & Droit Pub Date : 2024-08-01 DOI: 10.1016/j.meddro.2024.05.001

引用次数: 0

Les enjeux de la substitution des biosimilaires comparée à celle des génériques et des hybrides 用生物仿制药替代仿制药和混合药的挑战

IF 0.1

Medecine & Droit Pub Date : 2024-08-01 DOI: 10.1016/j.meddro.2024.01.001

{"title":"Les enjeux de la substitution des biosimilaires comparée à celle des génériques et des hybrides","authors":"","doi":"10.1016/j.meddro.2024.01.001","DOIUrl":"10.1016/j.meddro.2024.01.001","url":null,"abstract":"<div><p>The market of biological drugs is constantly expending, increasing healthcare costs. Facing the expensive cost of the high cost of these drugs, biosimilar drugs have gradually emerged. They are “similar” to the originator drug but less expensive, as they do not have to bear patent and R&D costs. However, these treatments present a high risk of immunogenicity, and are subject to a strict marketing authorization. It also raises the question of their interchangeability, to ensure a high penetration rate. Nevertheless, the mechanism of permutation by the prescriber is well developed. Their substitution by the pharmacist continues to be debated. Legislative and regulatory developments have constantly fluctuated between authorizing substitution and rejecting it. The latest Social Security Financing Act 2024 of December 26th, 2023 should have marked a clear broadening of the conditions for substitution, but the legislator opted for an unambitious solution. These reversals demonstrate the tensions surrounding the issue of biosimilar substitution. On one hand, patients’ fears of any potential adverse effects needs to be acknowledge by healthcare professionals; on the other, the substantial economic stakes involved underline the need to speed up the process. The question of marketing and substituting biosimilar drugs is here addressed in a comparative approach with generic and hybrid drugs. Because biosimilars, like generics and hybrids, are a fantastic opportunity to save funds and reinvest in research, while maintaining the same therapeutic excellence.</p></div>","PeriodicalId":41275,"journal":{"name":"Medecine & Droit","volume":"2024 187","pages":"Pages 67-72"},"PeriodicalIF":0.1,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140271017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fractures anciennes du scaphoïde. La difficile question de l’imputabilité 陈旧性肩胛骨骨折。难以归咎的问题

IF 0.1

Medecine & Droit Pub Date : 2024-08-01 DOI: 10.1016/j.meddro.2024.02.002

Clotilde Rougé-Maillart (Professeur de médecine légale et droit de la santé, expert près la cour d’appel d’Angers) , Florence Mallard (Chirurgien de la main)

引用次数: 0

À propos du diagnostic préimplantatoire des aneuploïdies (DPI-A). Les inconvénients de mots inappropriés et d’une réglementation inadaptée 非整倍体植入前诊断（PGD-A）。用词不当和规定不合适的弊端

IF 0.1

Medecine & Droit Pub Date : 2024-07-26 DOI: 10.1016/j.meddro.2024.05.003

Pierre Jouannet

{"title":"À propos du diagnostic préimplantatoire des aneuploïdies (DPI-A). Les inconvénients de mots inappropriés et d’une réglementation inadaptée","authors":"Pierre Jouannet","doi":"10.1016/j.meddro.2024.05.003","DOIUrl":"10.1016/j.meddro.2024.05.003","url":null,"abstract":"<div><div>Finding biological markers to assess the ability of embryos to develop is a major objective of research being carried out to improve the results of in vitro fertilization (IVF). Among these markers, the chromosomal content of embryonic cells has been the subject of numerous studies to identify euploid embryos which will be transferred as a priority into the uterus. In France, a clinical research program funded by the Ministry of Health was undertaken to evaluate the benefit of this strategy when IVF is carried out in women aged 35 to 41. This program was interrupted because its authorization was canceled by a court on the grounds that the search for aneuploidy in the embryo is a preimplantation genetic diagnosis (PGD) and that this type of analysis is not provided for in the governing law. The law says in fact that a PGD can only be carried out if “<em>has been previously and precisely identified, in one of the parents or one of their immediate ascendants in the case of a seriously disabling illness, with late revelation and prematurely endangering the vital prognosis</em>”. But the chromosomal analysis provided for in the research protocol is not a diagnosis, it is a test which identifies the embryos most capable of developing. Like all other techniques with the same goal, this test is not the responsibility of the law but of the good practice guide. Studies seeking to improve the results of IVF for the benefit of couples who use it should not be prevented.</div></div>","PeriodicalId":41275,"journal":{"name":"Medecine & Droit","volume":"2024 188","pages":"Pages 83-86"},"PeriodicalIF":0.1,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prescription et dispensation de médicaments en dehors des recommandations du dossier d’autorisation de mise sur le marché. Responsabilités des praticiens. L’exemple des fluoroquinolones 处方和配发非市场授权档案中推荐的药品。从业人员的责任。以氟喹诺酮类药物为例

IF 0.1

Medecine & Droit Pub Date : 2024-07-19 DOI: 10.1016/j.meddro.2024.07.001

Valérie Siranyan (professeure de droit pharmaceutique et d’économie de la santé) , Mathieu Guerriaud (maître de conférences en droit pharmaceutique et de la santé, pharmacovigilance et iatrogénie)

引用次数: 0

La rigueur scientifique de l’approche expertale 专家方法的科学严谨性

IF 0.1

Medecine & Droit Pub Date : 2024-07-14 DOI: 10.1016/j.meddro.2024.06.001

Ridouan Hammouch Professeur Maître de Conférence - Docteur en Droit Privé , Yamna Fatmi Professeure universitaire - P.E.S.

引用次数: 0

Le médecin confronté à l’IA (Intelligence artificielle) : Éthique et responsabilité 医生面对 AI（人工智能）：伦理与责任

IF 0.2

Medecine & Droit Pub Date : 2024-06-01 DOI: 10.1016/j.meddro.2024.02.001

Cécile Manaouil , Sylvain Chamot , Pascal Petit

引用次数: 0